Current concepts regarding calcium metabolism and bone health in sarcoidosis.
Study Goal
The researchers aimed to evaluate the safety and efficacy of vitamin D supplementation in sarcoidosis patients with bone health issues, particularly focusing on its impact on hypercalcemia and bone fragility.
Results Summary
The study found that vitamin D supplementation in sarcoidosis patients often leads to hypercalcemia and hypercalcuria without significant benefits for bone health or fracture risk. Elevated calcitriol levels, associated with disease activity, further complicate supplementation.
Population
Sarcoidosis patients, particularly postmenopausal women and those on corticosteroids.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Vitamin D supplementation | increase | hypercalcemia | sarcoidosis patients | - | may not be well tolerated | #1 |
Vitamin D supplementation | no change | bone health | sarcoidosis patients | - | without substantial benefit | #2 |
Vitamin D supplementation | no change | risk for fractures | sarcoidosis patients | - | without substantial benefit | #3 |
- | decrease | 25-hydroxy vitamin D | sarcoidosis patients | - | decreased | #4 |
- | increase | 1,25-dihydroxy vitamin D (calcitriol) | sarcoidosis patients | - | normal or often elevated | #5 |
- | increase | hypercalcemia | - | - | may often be associated | #6 |
- | increase | hypercalcuria | - | - | may often be associated | #7 |
PURPOSE OF REVIEW: Vitamin D supplementation is widespread used in the general population. In sarcoidosis, up to 50% of patients, especially postmenopausal women and those taking corticosteroids, show evidence of increased bone fragility. The purpose of this review is to provide an evidence-based rationale on how to treat sarcoidosis patients with bone health issues. RECENT FINDINGS: Evidence from observational studies show that decreased 25-hydroxy vitamin D is common in sarcoidosis. However, the great majority of sarcoidosis patents have normal or often elevated levels of 1,25-dihydroxy vitamin D (calcitriol), a marker associated with disease activity. High calcitriol levels may often be associated with hypercalcemia and hypercalcuria. The few interventional randomized controlled studies in the field, suggest that vitamin D supplementation may not be well tolerated because of hypercalcemia, moreover without substantial benefit on bone health and risk for fractures in these patients. SUMMARY: Vitamin D supplementation may be withheld in sarcoidosis patients with bone fragility, unless calcitriol levels are below normal limits. A treating scheme is proposed.